Statement by Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB)

Advocates demand that the Indian government take urgent action to ensure that every eligible person with TB has access to evidence-based, short-course treatment regimens.

Advocates urge the Indian government to issue compulsory licenses for patents on bedaquiline and delamanid to make the drugs more affordable and accessible.

Deadline for applications: 19 February 2021

TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction

Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.

TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on the TB Alliance’s new drug application for pretomanid.

Advocates call on WHO leadership to act immediately and correct specific technical errors in the WHO guidelines for the treatment of drug-resistant TB.

Statement by the Global TB Community Advisory Board to the High-level consultation on accelerating the development of the M72/AS01E tuberculosis vaccine candidate

Global TB CAB welcomes confirmation of safety of using bedaquiline and delamanid together, urges uptake.